Philips Respironics announced on Monday that it would suspend sales of all its breathing machines in the United States after coming to an agreement with the U.S. Food and Drug Administration (FDA) over ongoing issues with its sleep apnea devices.
“Patient safety and quality remain Philips’ highest priority across the company,” said Roy Jakobs, CEO of Royal Philips, in a press release. “Resolving the consequences of the Respironics recall for our patients and customers is a key focus area and I acknowledge and apologize for the distress and concern caused. We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward.”
